A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Trial Details
- NCT ID
- NCT06161025
- Phase
- PHASE2 / PHASE3
- Sponsor
- Daiichi Sankyo
- Status
- RECRUITING
- Cancer Type
- Ovarian Cancer
- Interventions
- R-DXd
- Paclitaxel
- Topotecan
- PLD
- Locations (sample)
- Anchorage, Alaska, United States|61.21806,-149.90028
- New Haven, Connecticut, United States|41.30815,-72.92816
- Coral Gables, Florida, United States|25.72149,-80.26838
- Deerfield Beach, Florida, United States|26.31841,-80.09977
- Lake Mary, Florida, United States|28.75888,-81.31784
Key Eligibility Criteria
- Sign and date the informed consent form prior to the start of any study-specific qualification procedures.
- Age ≥18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.
- Participants with histologically or cytologically documented high-grade serous ovarian cancer (OVC), high-grade endometrioid OVC, primary peritonea…
- For Phase 2 (Part A) Participants must have at least 1 lesion, not previously irradiated, amenable to biopsy, and must consent to provide a pretrea…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →